Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
102 participants
OBSERVATIONAL
2022-07-27
2022-12-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
NCT06041789
Bone Mineral Density, Disease Duration, and Activity in Ankylosing Spondylitis
NCT03866135
Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)
NCT01870557
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
NCT05228262
Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women
NCT05402852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Duloxetine Group
Patients who use duloxetine at least 3 months for chronic pain or fibromyalgia
Duloxetine
Patients who use duloxetine for chronic pain or fibromyalgia
Healthy Group
Age and sex matched 51 healthy individuals
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duloxetine
Patients who use duloxetine for chronic pain or fibromyalgia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients using duloxetine for at least 3 months due to chronic pain or fibromyalgia
Exclusion Criteria
* clinical conditions which cause secondary osteoporosis
* patients using medication that cause secondary osteoporosis
* pregnancy and malignity
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cukurova University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bayram Kelle
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Burak Demir, Dr.
Role: PRINCIPAL_INVESTIGATOR
Cukurova University Faculty of Medicine Department of Physical Medicine and Rehabilitation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Çukurova Üniversitesi
Adana, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Duloxetine on Bone Metabolism
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.